Story perspectives

Pfizer Cuts Drug Prices for Medicaid, Others Follow Suit

10/3/2025

Summary

Story summary

Pfizer will lower prices for many drugs sold to state Medicaid programs, potentially yielding savings.
The agreement covers new drugs in the United States at prices similar to Europe.
AstraZeneca and Novartis are launching similar direct-to-consumer programs.
The administration claims to have reached agreements with additional drug manufacturers, though they remain unidentified.

History

Historical Context

The Medicare Prescription Drug Improvement and Modernization Act of 2003 introduced a prescription drug benefit for seniors, significantly impacting U.S. pharmaceutical spending, which exceeded $600 billion in 2023. Recent agreements by Pfizer, AstraZeneca, and Novartis to lower drug prices reflect a growing trend towards enhancing medication affordability, indicating a potential shift in the pharmaceutical landscape and future pricing strategies.

1 of 2

Story summary

Pfizer will lower prices for many drugs sold to state Medicaid programs, potentially yielding savings.
The agreement covers new drugs in the United States at prices similar to Europe.
AstraZeneca and Novartis are launching similar direct-to-consumer programs.
The administration claims to have reached agreements with additional drug manufacturers, though they remain unidentified.

1 / 2